CHAPTER 1 - MARKET SUMMARY
Market Overview
Demand comes from production teams collecting samples without opening a sterile process stream. At Imexpharm's IMP4 plant, two lyophilized injectable lines and one blow-fill-seal injectable solution line were operating as of 2025. The mix matters commercially because collection volumes, port design and process stage affect which sampling assembly a site qualifies and how frequently it reorders.
The supplied 2024 market model records about 95,000 consumable units and 260 equipment units. This difference makes the installed equipment base a route to recurring revenue. Distributors need enough depth in qualified bags, valves and manifolds to support production schedules, while engineering teams need access to spare hardware and documentation for the smaller number of installations.
Market Value
USD 7 million
2025 estimate
Dominant Region
Southern Vietnam
2025 model
Dominant Segment
Single-Use Sampling Consumables
2025 model
Total Number of Players
10
2025 study coverage
Future Outlook
The market increases from USD 7 million in 2025 to USD 15 million in 2031 and USD 17 million in 2032 in the base case. The forecast CAGR of 14.00% (2025-2032) exceeds the historical CAGR of 10.25% (2020-2025). Growth depends on sterile line upgrades, broader use of closed sampling assemblies and higher consumption at sites that already buy them. Once a site qualifies an assembly, lot traceability and compatibility with existing ports support repeat orders. Equipment placements create the initial opportunity, while production throughput determines how much recurring revenue each placement generates.
The constrained case reaches USD 10 million by 2032 if qualification, commissioning and follow-on orders slip. The accelerated case reaches USD 32 million if more biologics and sterile injectable capacity comes online and sites order premium assemblies sooner. Across these cases, purchase orders for validated sampling points are a better indicator of near-term revenue than facility announcements. Bidiphar's sterile injectable project illustrates the distinction. Its 2026 invitation for EU-GMP consultancy indicates investment intent, with commercial consumable demand dependent on subsequent equipment qualification and production. Importers can use those milestones to time inventory commitments.
14.00% (2025-2032)
Forecast CAGR
USD 17 Mn
2032 Projection
Base Year
2025
Historical Period
2020-2025
Forecast Period
2025-2032
Historical CAGR
10.25% (2020-2025)
CHAPTER 2 - SCOPE OF REPORT
Scope of the Market
CHAPTER 3 - Key Stakeholders
Key Target Audience
The analysis supports investment, qualification, sourcing and distribution decisions across the sterile pharmaceutical production chain.
Investors
Recurring revenue, working capital, conversion, project timing
Corporates
Qualified accounts, portfolio coverage, pricing, replenishment margins
Government
GMP readiness, domestic sterile capacity, supply continuity
Operators
Sample integrity, validation time, fill rate, downtime
Financial institutions
Order visibility, inventory exposure, receivable days, covenants
CHAPTER 4 - Market Size & Growth
Market Size, Growth Forecast and Trends
This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers. Market values display at whole USD millions. Each value cell retains the underlying USD model value in its data-value-usd attribute. Growth rates use those underlying values.
Historical & Projected Market Size ($ Million)
Year-over-Year Growth Rate (%)
Market Value vs Volume Growth (%)
Historical Market Performance (2020-2025)
Market value increased at a CAGR of 10.25% (2020-2025), while combined shipment volume increased at a CAGR of 8.55% (2020-2025). The backcast depicts a smaller base of qualified sampling points early in the study period and higher shipments as facilities added capacity and upgraded GMP procedures. Within the reconstructed series, annual volume growth rises from 5.79% in 2021 to 10.38% in 2024. These are modeled demand and purchasing patterns. GMP listings document facility certification and scope, while shipment estimates depend on which listed sites actually operate in-scope lines.
Forecast Market Outlook (2025-2032)
The base case reaches USD 17 million by 2032, with a value CAGR of 14.00% (2025-2032) and a combined volume CAGR of 12.00% (2025-2032). The remaining difference is consistent with higher revenue per shipment unit as qualified multi-port assemblies, higher-spec hardware and associated support enter the mix. Blended invoice value rises to USD 72.55 per shipment unit in 2032. System installations influence near-term revenue, but consumable orders spread growth across production runs. The forecast extension keeps the supplied annual growth assumptions and therefore depends on continuous conversion of new sampling points into recurring purchases.
CHAPTER 5 - Market Data
Market Breakdown
The table separates shipment growth, consumable demand and the blended invoice yield. For distributors, consumable units are the more useful stocking measure. The blended yield reflects both equipment mix and associated service revenue.
Year | Market Size (USD Mn) | YoY Growth (%) | Combined Shipment Volume (Units) | Blended Invoice Value (USD per Shipment Unit) | Consumable Shipments (Units) | Period |
|---|---|---|---|---|---|---|
| 2020 | $4 Mn | +First study year | 70,800 | 59.32 | Forecast | |
| 2021 | $5 Mn | +7.14% | 74,900 | 60.08 | Forecast | |
| 2022 | $5 Mn | +8.44% | 79,600 | 61.31 | Forecast | |
| 2023 | $5 Mn | +10.25% | 86,300 | 62.34 | Forecast | |
| 2024 | $6 Mn | +11.52% | 95,260 | 62.99 | Forecast | |
| 2025 | $7 Mn | +14.00% | 106,691 | 64.11 | Forecast | |
| 2026 | $8 Mn | +14.04% | 119,494 | 65.28 | Forecast | |
| 2027 | $9 Mn | +13.97% | 133,833 | 66.43 | Forecast | |
| 2028 | $10 Mn | +13.95% | 149,893 | 67.58 | Forecast | |
| 2029 | $12 Mn | +14.02% | 167,881 | 68.80 | Forecast | |
| 2030 | $13 Mn | +14.00% | 188,027 | 70.03 | Forecast | |
| 2031 | $15 Mn | +14.00% | 210,590 | 71.28 | Forecast | |
| 2032 | $17 Mn | +14.00% | 235,861 | 72.55 | Forecast |
Combined Shipment Volume
235,861 units (2032, Vietnam forecast). Shipment planning needs separate run rates for assemblies and equipment. Imexpharm's two injectable powder lines illustrate how a single facility can generate demand from more than one workflow.
Blended Invoice Value
USD 64.11 per shipment unit (2025, Vietnam model). Quote evaluation should compare like-for-like assemblies. One supplier's standard sampling manifold uses 60 mL collection bottles and a 0.2 micron vent filter, specifications that affect which products can substitute for one another.
Consumable Shipments
106,400 units (2025, Vietnam model). Inventory forecasts should distinguish single-point kits from multi-point sets. The NovaSeptum SURe specification shows how different connection choices can change which consumables a qualified workflow can accept.
CHAPTER 6 - Segmentation
Market Segmentation Framework
The product-led framework separates what a facility buys, where it uses the product and how the purchase reaches the site. Each dimension is a separate view of the same domestic revenue pool.
No of Segments
7
Dominant Segment
Product Type
Fastest Growing Segment
Application
Product Type
Application
End User
Technology
Price Tier
Distribution Channel
Geography
Key Segmentation Takeaways
Product Type is the primary view for commercial planning. Application shows where new line investments can change the demand mix. These dimension labels identify commercial priorities. Growth and shares apply to the underlying categories.
Product Type
is led by Single-Use Sampling Consumables. Once operators qualify a bag, valve or manifold for a sampling point, production schedules drive repeat ordering. Procurement commonly evaluates the sterile pack, connector geometry and lot documentation together. A supplier's practical revenue advantage comes from keeping approved configurations available and giving sites enough notice to validate changes.
Application
shows the strongest modeled shift toward Upstream Process Sampling, where additional bioreactor and fermentation runs create more sampling events. At sites with sufficiently intensive monitoring, automated collection may also support traceability and remove repetitive handling. Suppliers can assess the opportunity by mapping each qualified port to the number of runs and samples per run.
CHAPTER 7 - Regional Analysis
Regional Analysis
Vietnam ranks fourth by estimated 2025 revenue in a five-country comparison with Singapore, Indonesia, Thailand and Malaysia. These markets offer useful comparisons because they have distinct combinations of biologics manufacturing, vaccine production and regulated sterile operations. Singapore's biopharmaceutical production base gives it a different equipment and price mix from Vietnam.
Regional Ranking
4th of 5 selected markets (2025)
Vietnam Market Size
USD 7 Mn (2025 estimate)
Vietnam CAGR
14.00% (2025-2032)
Regional Ranking
4th of 5 selected markets (2025)
Vietnam Market Size
USD 7 Mn (2025 estimate)
Vietnam CAGR
14.00% (2025-2032)
Regional Analysis (Current Year)
Regional Analysis Comparison
| Metric | Vietnam | Singapore | Indonesia | Thailand | Malaysia |
|---|---|---|---|---|---|
| Market Size (USD Mn, 2025) | 7 | 11 | 9 | 8 | 6 |
| CAGR (2025-2032) | 14.00% (2025-2032) | 10.41% (2025-2032) | 12.08% (2025-2032) | 12.28% (2025-2032) | 10.41% (2025-2032) |
Market Position
Vietnam ranks fourth at USD 7 million in 2025. Its established sterile drug lines support demand, while Malaysia's integrated insulin capacity illustrates why individual facilities can materially affect a smaller market.
Growth Advantage
Vietnam's modeled CAGR of 14.00% (2025-2032) exceeds Thailand's 12.28% (2025-2032) and Indonesia's 12.08% (2025-2032). Vietnam starts from a smaller base, where commissioning a few qualified lines can move growth materially.
Competitive Strengths
Three injectable lines at IMP4 and a domestic GMP framework with WHO, PIC/S and EU appendices give suppliers identifiable qualification requirements and reference workflows for local applications support.
CHAPTER 8 - INDUSTRY ANALYSIS
Growth Drivers, Challenges & Opportunities
The growth drivers affect different points in the buying cycle. Compliance shapes product qualification, commissioning creates installation demand, and commercial production determines repeat order volumes.
Growth Drivers
Sterile GMP Upgrades
2025, Vietnam
- EU GMP Annex 1 (2022, EU) places sterile connections within the wider contamination control strategy, creating demand for suppliers able to document the complete sampling assembly.
- WHO TRS 1044 Annex 2 (2022, international) provides a sterile manufacturing reference, making supplier support for installation and operator qualification more valuable at audit preparation.
- The October 2025 GMP register update (2025, Vietnam) gives commercial teams a way to identify sites and screen their certificate scope before allocating field engineering time.
Injectable and Biologics Capacity
2025, Vietnam
- Two lyophilized powder lines at IMP4 (2025, Vietnam) demonstrate the value of mapping purchases to process lines, with separate qualification decisions even within a single site.
- Bidiphar's sterile injectable consultancy invitation (2026, Vietnam) creates an early opportunity to specify ports and validation deliverables before equipment procurement.
- Decision 1165/QD-TTg (2023, Vietnam) prioritizes pharmaceutical industry development through 2030, supporting a project pipeline that equipment suppliers can screen for qualifying sterile capacity.
Repeat Orders for Closed Single-Use Assemblies
2022, EU
- NovaSeptum SURe connection specifications (manufacturer data sheet) show why a substitute with different tubing or connectors can require review, which helps approved suppliers retain repeat orders.
- TakeOne's modular configurations (manufacturer portfolio) let teams choose containers and process interfaces at qualification. Suppliers can then stock approved configurations against the buyer's production schedule.
- Bio-Simplex 60 mL bottles (manufacturer specification) illustrate why firms with several validated sample volumes can consolidate recurrent kit purchasing without changing their approved interfaces.
Market Challenges
Import Lead Times and Qualified Stock
2022, EU
- WHO TRS 1044 Annex 2 (2022, international) makes supplier qualification and sterile packaging controls relevant to inventory planning. Local safety stock ties up cash but limits exposure to expedited purchases.
- Pre-irradiated bags in the Keofitt catalog (2024, supplier specification) illustrate why stock substitutions must preserve sterile packaging and documentation, reducing the pool of usable emergency inventory.
- Two connection options described for NovaSeptum SURe (manufacturer data sheet) show how interface choice fragments reorder inventory. Distributors need SKU-level forecasts to avoid surplus in the wrong configurations.
Validation Cost and Switching Friction
2022, EU
- Single-use integrity and compatibility controls in WHO TRS 1044 Annex 2 (2022, international) can add testing and documentation costs when a material, connection or assembly changes.
- Circular 28/2025/TT-BYT GMP inspection appendices (2025, Vietnam) reinforce the value of auditable records. Smaller buyers may phase upgrades across lines to manage engineering and documentation workloads.
- Separate manual and automated valve designs (manufacturer catalog) mean a retrofit may require new operator procedures or controls. Quoting hardware alone understates the conversion cost.
Uneven Sterile Line Commissioning
2026, Vietnam
- Decree 163/2025/ND-CP (2025, Vietnam) provides implementing measures for the Pharmacy Law. Commercial forecasts need to distinguish regulatory milestones from equipment acceptance and routine line use.
- Three IMP4 injectable lines (2025, Vietnam) operate across distinct formats. Site-level sales models can overstate immediate demand if they treat all lines and consumable configurations as interchangeable.
- The 2030 national strategy horizon (2023, Vietnam) spans multiple investment cycles. Supplier inventory commitments should follow individual commissioning and qualification milestones to limit exposure to project slippage.
Market Opportunities
Validation Support for Closed-Sampling Retrofits
2022, EU
- WHO TRS 1044 Annex 2 (2022, international) provides a basis for commissioning and training packages that can be quoted separately from hardware where customers require documentation support.
- VESTA's modular sampling system (manufacturer specification) allows integrators to match valves to several sampling locations, helping retrofit buyers target selected ports within an existing line.
- Circular 28/2025/TT-BYT (2025, Vietnam) makes qualification documentation a priority for buyers. A commercially viable service requires local engineering capacity and agreed acceptance criteria.
Local Stocking for Approved Consumables
2022, EU
- TakeOne modular product families (manufacturer portfolio) give distributors a defined set of configurations to sell through call-off contracts, linking replenishment orders to buyer production schedules.
- Single-use assembly integrity controls in WHO TRS 1044 Annex 2 (2022, international) make traceable local inventory valuable to quality and procurement teams that need predictable replacements.
- Keofitt's sterile pack specification (2024, supplier catalog) illustrates the need for lot, expiry and packaging checks. Distributors need buyer forecasts to keep buffers commercially viable.
Automated Sampling for Bioprocess Lines
manufacturer portfolio
- Temperature-controlled fraction collection (manufacturer specification) gives automation suppliers a way to package collection and holding capability with the sampler where workflows justify it.
- Annex 1 closed-system provisions (2022, EU) support evaluating automated sampling during line design. Biologics manufacturers benefit when integration preserves a validated fluid path and reduces manual intervention.
- Decision 1165/QD-TTg (2023, Vietnam) gives suppliers a basis to screen prospective sites. Pilots should establish sampling frequency, analyzer integration requirements and ownership of maintenance.
CHAPTER 9 - Competitive Landscape
Competitive Landscape Overview
Global bioprocess portfolios compete with valve specialists and automation suppliers. Qualification and local supply reliability shape repeat purchasing. Market shares below are 2024 Vietnam model proxies for named suppliers, with MDI Membrane included as a product benchmark.
Market Share Distribution
Top 5 Players
Market Dynamics
8 new entrants in the past 5 years, indicating strong market attractiveness and growth potential.
Company Name | Market Share (2024 Vietnam Model) | Headquarters | Founding Year | Core Market Focus |
|---|---|---|---|---|
Merck KGaA | 20.00% | Darmstadt, Germany | 1668 | NovaSeptum sterile process sampling assemblies. |
Sartorius Stedim Biotech | 15.00% | - | - | TakeOne single-use samplers and aseptic containers. |
Thermo Fisher Scientific | 14.17% | - | - | Single-use bioreactor and fermentor sampling components. |
Cytiva | 11.67% | - | - | Bioprocess fluid handling, including the legacy Pall Life Sciences portfolio. |
Saint-Gobain Life Sciences | 9.17% | - | - | Bio-Simplex single-use sampling manifolds. |
Keofitt A/S | 5.83% | - | - | Process sampling valves and sterile collection bags. |
GEA Group | 3.33% | - | - | VESTA sterile sampling valves and modular sampling systems. |
KIESELMANN GmbH | 3.00% | Knittlingen, Germany | 1937 | Manual and automated aseptic sampling valves. |
Flownamics Inc. | 2.00% | Madison, United States | 1995 | Seg-Flow automated sampling and fraction collection. |
MDI Membrane | - | - | - | ASESS gamma-irradiated sampling assemblies, used here as a product benchmark. |
Cross Comparison Parameters
The report provides detailed cross-comparison of key players across 10 performance parameters to identify competitive strengths and weaknesses.
Qualified Sampling Configurations
Local Stock Order Fill Rate
Consumables Revenue Mix
Gross Margin on Qualified Assemblies
Analysis Covered
Market Share Analysis:
Compares modeled domestic revenue concentration across named and residual suppliers.
Cross Comparison Matrix:
Compares portfolio breadth, local fulfillment, recurring sales and assembly margins.
SWOT Analysis:
Evaluates validation strengths, distribution gaps, upgrade demand and substitution risk.
Pricing Strategy Analysis:
Separates hardware, consumables, qualification fees and recurring replenishment contract terms.
Company Profiles:
Maps suppliers to sampling workflows, products and modeled revenue positions.
CHAPTER 10 - REPORT TOC
Table of Contents
Market Assessment Phase
Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts.
Go-To-Market Strategy Phase
15 chapters
Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook.
Survey Phase
8 chapters
Demand-side primary research conducted through structured interviews and online surveys with end users across priority metros and Tier 2/3 cities to capture consumption behavior, unmet needs, and purchase drivers.
Complete Report Coverage
201+ detailed sections covering every aspect of the market
143
Assessment Sections
58
Strategy Sections
CHAPTER 11 - Our Approach
Research Methodology
Desk Research
- Review Vietnamese GMP facility registers
- Verify sterile line operating disclosures
- Map qualified sampling product catalogs
- Screen peer pharmaceutical manufacturing profiles
Primary Research
- Target sterile manufacturing quality directors
- Interview bioprocess engineers about workflows
- Question distributors on stocking practices
- Test procurement criteria with buyers
Validation and Triangulation
- Design coverage for 250 respondents
- Reconcile end-customer invoice revenue
- Compare shipments with facility demand
- Test assumptions against peer markets
CHAPTER 12 - FAQ
FAQs
Still have questions?
Our research team is here to help you find the right solution
CHAPTER 13 - Related Research
Explore Related Reports
Expand your market intelligence with complementary research across regions and adjacent markets.
Regional/Country ReportsRelated market analysis across key regions
Related market analysis across key regions
No regional reports found.
Adjacent ReportsRelated markets and complementary research
Related markets and complementary research
- Thailand Single-Use Bioprocessing Systems Market
- KSA Aseptic Filling Equipment Market
- Vietnam Sterile Filtration Products Market
- Malaysia Pharmaceutical Process Validation Services Market
- South Africa Cleanroom Environmental Monitoring Market
500+
Market Research Reports
50+
Countries Covered
15+
Industry Verticals